A Pharmacor Analyst Call from Decision Resources

To ensure that our emails get to your inbox, please add Decision_Resources@mail.vresp.com to your email address book or safe senders list.
PLEASE DO NOT REPLY TO THIS EMAIL; CONTACT YOUR ACCOUNT REPRESENTATIVE DIRECTLY.

If this message does not display properly, please click here to launch your browser.

How Will Key Agents in Development Impact the Type 2 Diabetes Market? News from the ADA’s 70th Annual Scientific Sessions

Based on our Pharmacor Type 2 Diabetes advisory service, Decision Resources is offering an exclusive analyst call entitled How Will Key Agents in Development Impact the Type 2 Diabetes Market? News from the ADA’s 70th Annual Scientific Sessions. Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service.

Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.

Clinical trial data were presented for key compounds in several promising drug classes at this year’s 70th Annual Scientific Sessions of the American Diabetes Association. Among the most widely anticipated trials were safety and efficacy data from Roche’s once-weekly GLP-1 analogue taspoglutide and Novo Nordisk’s long-acting insulin degludec. Additionally, focus on the novel SGLT2 inhibitor drug class is intensifying as compounds from Johnson & Johnson (canagliflozin), Astellas (ASP-1941) and Boehringer Ingelheim (BI-10773) continue to jockey for position behind Bristol-Myers Squibb/AstraZeneca’s leading agent, dapagliflozin.

This 15-minute analyst call, presented by Decision Resources Analyst Yannick Maneuf, Ph.D., will answer the following questions:

How do the different long-acting GLP-1 analogues compare against one another in safety and efficacy, and how does the competitive landscape look following Roche’s announcement of a delay for taspoglutide?
What attributes will allow each of the different SGLT2 inhibitors in development to differentiate from one another and what opinions do thought leaders have about their mechanism of action?
What do key opinion leaders say about Novo Nordisk’s ultra-long-acting insulin degludec and how does the drug’s pharmacokinetic profile compare against Sanofi-Aventis’s Lantus (insulin glargine)?
What is the medical community’s current view of the potential link between Lantus and cancer risk? Is Lantus cleared from any link to cancer?

Dr. Maneuf and Decision Resources Director of Metabolic Disorders Donny Wong, Ph.D., will conduct a live Q & A session after the presentation.

Registration

How Will Key Agents in Development Impact the Type 2 Diabetes Market? News from the ADA’s 70th Annual Scientific Sessions

July 15, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).

To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.

In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com

In Europe — Kaj van Langendonck at +32-2-357-06-14 or kvanlangendonck@decisionresources.be

In Japan — Makiko Yoshimoto at +81-3-5401-2615 or makiko@dresources.jp

Date & Time
Thursday, July 15, 2010
10 a.m. U.S. Eastern Time,
4 p.m. Central European Time

Duration
15 minutes

Yannick Maneuf, Ph.D. is an analyst in the metabolic disorders group at Decision Resources. His scientific career includes over 10 years directing drug discovery and development efforts in the biotech sector. Dr. Maneuf has published 18 articles in peer-reviewed journals focusing on the metabolic disorders, pain, and inflammation therapeutic areas and he currently serves as an associate editor for the International Journal of Pharmacology. He earned a Ph.D. in Neuroscience from the University of Manchester, where he studied neural transmission in the basal ganglia, and he holds a B.Sc. in Cell Biology and Physiology from the University of Bordeaux.

Terms of Use | Privacy Policy | Contact Us | Careers

Decision Resources • 260 Charles Street • Waltham, MA 02453

Register to receive our latest offers. You are receiving this email because you have previously requested information from Decision Resources.

© 2010 Decision Resources, Inc. All rights reserved.